The current gold-standard treatment available to people with late-stage neovascular AMD is monoclonal antibodies targeting vascular endothelial growth factor (VEGF), a potent pro-angiogenic factor whose expression is regulated by hypoxia and found at increased levels in the eyes of AMD patients.29 Here, VEGFA is linked to age-related macular degeneration.